Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Ross

Showing results (91-100 of 225) with videos related to

Pageof 23
Sort By:
Therapeutic Drug Monitoring|February 2, 2023
Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced CardiotoxicityAngela Siemens, Shahrad Rod Rassekh, Colin J D Ross, et al.
Annual Review of Pharmacology and Toxicology|October 2, 2020
Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical SettingsWan-Chun Chang, Reo Tanoshima, Colin J D Ross, et al.
Pediatrics|April 1, 2000
Potential to prevent carbon dioxide rebreathing of commercial products marketed to reduce sudden infant death syndrome riskP L Carolan, W B Wheeler, J D Ross, et al.
Anaesthesia and Intensive Care|August 1, 1989
Anaphylaxis to thiopentone: an unusual outbreak in a single hospitalM M Fisher, J D Ross, D G Harle, et al.
Frontiers in Genetics|March 6, 2015
Use of pharmacogenomics in pediatric renal transplant recipientsMara Medeiros, Gilberto Castañeda-Hernández, Colin J D Ross, et al.
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|January 23, 1998
Biomechanical considerations of mandibular lengthening and widening by gradual distraction using a computer modelM L Samchukov, J B Cope, R P Harper, et al.
Current Opinion in Pediatrics|August 16, 2020
Prevention of adverse drug effects: a pharmacogenomic approachErika N Scott, Jafar S Hasbullah, Bruce C Carleton, et al.
Sexually Transmitted Infections|July 21, 2001
Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotypeM Shahmanesh, H Jaleel, Y DeSilva, et al.
Physical Therapy|August 3, 2013
Promoting neuroplasticity for motor rehabilitation after stroke: considering the effects of aerobic exercise and genetic variation on brain-derived neurotrophic factorCameron S Mang, Kristin L Campbell, Colin J D Ross, et al.
The Pharmacogenomics Journal|October 26, 2016
The global spectrum of protein-coding pharmacogenomic diversityG E B Wright, B Carleton, M R Hayden, et al.
Pageof 23

Showing results (91-100 of 225) with videos related to

Sort By:
Pageof 23
Therapeutic Drug Monitoring|February 2, 2023
Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced CardiotoxicityAngela Siemens, Shahrad Rod Rassekh, Colin J D Ross, et al.
Annual Review of Pharmacology and Toxicology|October 2, 2020
Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical SettingsWan-Chun Chang, Reo Tanoshima, Colin J D Ross, et al.
Pediatrics|April 1, 2000
Potential to prevent carbon dioxide rebreathing of commercial products marketed to reduce sudden infant death syndrome riskP L Carolan, W B Wheeler, J D Ross, et al.
Anaesthesia and Intensive Care|August 1, 1989
Anaphylaxis to thiopentone: an unusual outbreak in a single hospitalM M Fisher, J D Ross, D G Harle, et al.
Frontiers in Genetics|March 6, 2015
Use of pharmacogenomics in pediatric renal transplant recipientsMara Medeiros, Gilberto Castañeda-Hernández, Colin J D Ross, et al.
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|January 23, 1998
Biomechanical considerations of mandibular lengthening and widening by gradual distraction using a computer modelM L Samchukov, J B Cope, R P Harper, et al.
Current Opinion in Pediatrics|August 16, 2020
Prevention of adverse drug effects: a pharmacogenomic approachErika N Scott, Jafar S Hasbullah, Bruce C Carleton, et al.
Sexually Transmitted Infections|July 21, 2001
Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotypeM Shahmanesh, H Jaleel, Y DeSilva, et al.
Physical Therapy|August 3, 2013
Promoting neuroplasticity for motor rehabilitation after stroke: considering the effects of aerobic exercise and genetic variation on brain-derived neurotrophic factorCameron S Mang, Kristin L Campbell, Colin J D Ross, et al.
The Pharmacogenomics Journal|October 26, 2016
The global spectrum of protein-coding pharmacogenomic diversityG E B Wright, B Carleton, M R Hayden, et al.
Pageof 23